February 25, 2017 7:28 AM ET

Biotechnology

Company Overview of Chimerix, Inc.

Company Overview

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the United States. The company’s lead product candidate is brincidofovir (CMX001), a nucleotide analog, which is in Phase III clinical trials for the prevention of cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant (HCT) recipients and in kidney transplant recipients, as well as to treat adenovirus infection in allogeneic HCT patients. It is also developing CMX157, a nucleotide analog that is in Phase II clinical stage for the treatment of HIV and hepatitis B virus infection. The company’s preclinical testing product comprises CMX669, a co...

2505 Meridian Parkway

Suite 100

Durham, NC 27713

United States

Founded in 2000

90 Employees

Phone:

919-806-1074

Fax:

919-806-1146

Key Executives for Chimerix, Inc.

Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $505.7K
Chief Financial Officer, Senior Vice President and Corporate Secretary
Age: 58
Total Annual Compensation: $332.5K
Chief Medical Officer
Age: 47
Total Annual Compensation: $493.0K
Chief Commercial Officer
Age: 52
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2015.

Chimerix, Inc. Key Developments

Chimerix Announces Final Data from Advise Trial of Brincidofovir at BMT Tandem Meetings

Chimerix announced the presentation of final data from the AdVise trial of brincidofovir for the treatment of adenovirus (AdV) infection in allogeneic hematopoietic cell transplant (HCT) recipients at the BMT Tandem Meetings held February 22-26, 2017 in Orlando, FL. The AdVise trial was an open-label, multicenter study designed to evaluate the efficacy, safety and overall tolerability of oral brincidofovir for the treatment of adenovirus infection. Pediatric and adult subjects were assigned to one of three cohorts: Cohort A, comprised of allogeneic HCT recipients with asymptomatic or limited adenovirus infection; Cohort B, comprised of allogeneic HCT recipients with disseminated adenovirus disease; and Cohort C, comprised of autologous HCT recipients, solid organ transplant recipients and other patients with serious adenovirus infections. All subjects were to receive 12 weeks of oral brincidofovir and were followed for at least 36 weeks. This final analysis includes 158 allogeneic HCT recipients assigned to Cohorts A (23 adult and 42 pediatric patients) and B (35 adult and 58 pediatric patients). In the AdVise trial, declines in AdV viral load of =2 log10 c/mL or below the limit of detection at Week 4 were observed in 76% of pediatric patients and 45% of adult patients. Notably, this antiviral effect was observed even in HCT recipients who did not yet have immune recovery. In Cohort A, 55% of patients with baseline low immunity (CD4 counts).

Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects

Chimerix announced preliminary data from an ongoing Phase 1 study to investigate the safety, tolerability and plasma/intracellular concentration of intravenous (IV) brincidofovir (BCV) following single escalating doses in healthy adult subjects. In this ongoing study, IV administration of BCV demonstrated a favorable tolerability profile at both doses tested to date. No drug related adverse events (AEs) or laboratory abnormalities were identified. Notably, gastrointestinal (GI) side effects were absent. Blood plasma concentrations of BCV which have previously demonstrated anti-viral potency in cytomegalovirus (CMV) prevention and adenovirus treatment were achieved with IV doses that were one tenth of those required with oral dosing. This suggests that even the lowest tested IV dose of brincidofovir should provide antiviral activity. A total of 40 healthy subjects will be randomized to receive either a single dose of IV BCV or IV placebo in one of four cohorts. To date, 16 subjects have enrolled into 2 dose groups; 8 subjects were randomized in each of Cohorts 1 (IV BCV 10 mg) and 2 (IV BCV 25 mg). It is anticipated that two additional cohorts will be enrolled. As the new IV formulation of BCV progresses in clinical studies, BCV remains in development as an orally-administered lipid conjugate nucleotide for the treatment of adenovirus in hematopoietic cell transplant recipients and other immunocompromised patients, and as a medical countermeasure for the treatment of smallpox.

Chimerix, Inc. Announces Executive Appointments

Chimerix, Inc. announced the appointments of Randall Lanier, PhD, as chief science officer and Roy W. Ware, PhD, MBA, as chief manufacturing and technology officer. Dr. Lanier will continue to oversee preclinical screening programs, biology and virology. Dr. Ware will oversee manufacturing, clinical trial material sourcing, medicinal and process chemistry, and analytical and pharmaceutical development. Together they will lead the company discovery effort. During his tenure at the company, Dr. Lanier has led teams that designed successful studies of brincidofovir for smallpox, characterized the resistance/activity profile of brincidofovir for multiple viruses, and explored the potential of the company chemical library to address unmet medical needs. Recently these efforts led to the identification of a clinical candidate, CMX521, for norovirus, the leading cause of viral gastroenteritis worldwide. Dr. Lanier has nearly 25 years of experience in the discovery and development of antivirals; he has focused much of his career on understanding the activity, mechanism, and resistance profiles of nucleoside analogs used for prevention and treatment of viral disease caused by HIV, CMV, adenovirus and poxviruses. In his previous position as vice president, chemistry at the company, Dr. Ware led the chemistry effort for discovery and development programs, including structure/activity evaluation, chemical process development, and manufacturing of CMX521. He also contributed to the patent programs for brincidofovir, securing a patent extension to 2034, and CMX157 (licensed to ContraVir), securing a patent extension to 2033. Prior to joining the company, Dr. Ware held multiple positions in research including as a research scientist at PharmaCore, Inc.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Chimerix, Inc., please visit www.chimerix.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.